BioCentury
ARTICLE | Company News

Cornerstone Therapeutics sales and marketing update

November 25, 2013 8:00 AM UTC

Cornerstone launched Bethkis tobramycin inhalation solution in the U.S. to manage Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). The wholesale acquisition cost for a 28-day ...